Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.-MedSci.cn

Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.

Kopetz, S; Lonardi, S; McDermott, RS; Aglietta, M; Hendlisz, A; Morse, M; Leach, JW; Neyns, B; Chan, E; Chen, F; Wong, KYM; Lee, JJ; Garcia-Alfonso, P; Hill, AG; Lenz, HJ; Desai, J

JOURNAL OF CLINICAL ONCOLOGY, 2017; 35 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务